ZA201403276B - Low dose pharmaceutical composition - Google Patents
Low dose pharmaceutical compositionInfo
- Publication number
- ZA201403276B ZA201403276B ZA2014/03276A ZA201403276A ZA201403276B ZA 201403276 B ZA201403276 B ZA 201403276B ZA 2014/03276 A ZA2014/03276 A ZA 2014/03276A ZA 201403276 A ZA201403276 A ZA 201403276A ZA 201403276 B ZA201403276 B ZA 201403276B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- low dose
- dose pharmaceutical
- low
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1696MU2013 IN2013MU01696A (Direct) | 2013-05-10 | 2014-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201403276B true ZA201403276B (en) | 2015-07-29 |
Family
ID=50979804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/03276A ZA201403276B (en) | 2013-05-10 | 2014-05-08 | Low dose pharmaceutical composition |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20160120847A1 (Direct) |
| EP (1) | EP2994131A1 (Direct) |
| JP (1) | JP2016518398A (Direct) |
| CN (1) | CN105377256A (Direct) |
| AP (1) | AP2015008875A0 (Direct) |
| AU (1) | AU2014264421A1 (Direct) |
| BR (1) | BR112015028257A2 (Direct) |
| CA (1) | CA2911671A1 (Direct) |
| EC (1) | ECSP15051434A (Direct) |
| HK (1) | HK1215191A1 (Direct) |
| IN (1) | IN2013MU01696A (Direct) |
| MX (1) | MX2015015553A (Direct) |
| PE (1) | PE20151934A1 (Direct) |
| PH (1) | PH12015502557A1 (Direct) |
| RU (1) | RU2015149544A (Direct) |
| SG (1) | SG11201509308TA (Direct) |
| WO (1) | WO2014181108A1 (Direct) |
| ZA (1) | ZA201403276B (Direct) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10265301B2 (en) | 2015-06-17 | 2019-04-23 | Dispersol Technologies, Llc | Formulations of deferasirox and methods of making the same |
| RU2616267C1 (ru) * | 2016-01-25 | 2017-04-13 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения |
| EP3429562A1 (en) * | 2016-03-17 | 2019-01-23 | Lupin Limited | Compositions of deferasirox |
| CN105853367B (zh) * | 2016-05-10 | 2019-07-12 | 广州加德恩医药有限公司 | 地拉罗司固体分散体的制备方法及其药物制剂 |
| CA3029543C (en) * | 2016-07-05 | 2021-11-23 | Jubilant Generics Limited | Immediate release pharmaceutical composition of iron chelating agents |
| CZ2017255A3 (cs) * | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
| JPWO2018230713A1 (ja) * | 2017-06-16 | 2020-04-16 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| CN110944668A (zh) | 2017-06-16 | 2020-03-31 | 学校法人同志社 | 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用 |
| DK3684344T3 (da) * | 2017-10-25 | 2025-08-04 | Chiesi Farm Spa | Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf |
| CN109646423A (zh) * | 2018-12-03 | 2019-04-19 | 泓博元生命科技（深圳）有限公司 | 含nadh的生物高分子纳米球及其制备方法与应用 |
| CN115400088B (zh) * | 2022-09-06 | 2023-07-07 | 上海奥科达医药科技股份有限公司 | 一种地拉罗司药物组合物及其制备方法 |
| CN115154428B (zh) * | 2022-09-06 | 2023-01-10 | 上海奥科达医药科技股份有限公司 | 一种地拉罗司药物组合物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| GB0223978D0 (en) * | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
| GB0408078D0 (en) | 2004-04-08 | 2004-05-12 | Novartis Ag | Organic compounds |
| RU2008119410A (ru) | 2005-10-19 | 2009-11-27 | Новартис АГ (CH) | Диспергируемые таблетки, включающие деферасирокс |
| WO2009016359A1 (en) * | 2007-07-27 | 2009-02-05 | Pliva Hrvatska D.O.O. | New forms of deferasirox |
| EP2062572A1 (en) | 2007-11-19 | 2009-05-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions |
| WO2010035282A1 (en) | 2008-09-24 | 2010-04-01 | Matrix Laboratories Limited | Pharmaceutical compositions comprising deferasirox |
| PE20170468A1 (es) * | 2010-10-01 | 2017-04-26 | Cipla Ltd | Composicion farmaceutica que comprende deferasirox |
| JP2014529997A (ja) * | 2011-09-23 | 2014-11-17 | ウニヴェルズィテート シュトゥットガルト | 免疫グロブリン結合ドメインを使った血清中半減期延長 |
-
2014
- 2014-05-08 HK HK16103262.7A patent/HK1215191A1/zh unknown
- 2014-05-08 IN IN1696MU2013 patent/IN2013MU01696A/en unknown
- 2014-05-08 EP EP14731760.6A patent/EP2994131A1/en not_active Withdrawn
- 2014-05-08 AU AU2014264421A patent/AU2014264421A1/en not_active Abandoned
- 2014-05-08 PE PE2015002380A patent/PE20151934A1/es not_active Application Discontinuation
- 2014-05-08 WO PCT/GB2014/051400 patent/WO2014181108A1/en not_active Ceased
- 2014-05-08 AP AP2015008875A patent/AP2015008875A0/xx unknown
- 2014-05-08 SG SG11201509308TA patent/SG11201509308TA/en unknown
- 2014-05-08 BR BR112015028257A patent/BR112015028257A2/pt not_active IP Right Cessation
- 2014-05-08 ZA ZA2014/03276A patent/ZA201403276B/en unknown
- 2014-05-08 MX MX2015015553A patent/MX2015015553A/es unknown
- 2014-05-08 CN CN201480038832.0A patent/CN105377256A/zh active Pending
- 2014-05-08 RU RU2015149544A patent/RU2015149544A/ru not_active Application Discontinuation
- 2014-05-08 US US14/890,235 patent/US20160120847A1/en not_active Abandoned
- 2014-05-08 CA CA2911671A patent/CA2911671A1/en not_active Abandoned
- 2014-05-08 JP JP2016512416A patent/JP2016518398A/ja active Pending
-
2015
- 2015-11-10 PH PH12015502557A patent/PH12015502557A1/en unknown
- 2015-12-10 EC ECIEPI201551434A patent/ECSP15051434A/es unknown
-
2016
- 2016-02-18 US US15/047,091 patent/US20160158202A1/en not_active Abandoned
- 2016-10-12 US US15/291,728 patent/US20170095453A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/650,195 patent/US20170312254A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201509308TA (en) | 2015-12-30 |
| US20160158202A1 (en) | 2016-06-09 |
| AP2015008875A0 (en) | 2015-11-30 |
| MX2015015553A (es) | 2016-06-17 |
| RU2015149544A (ru) | 2017-06-16 |
| BR112015028257A2 (pt) | 2017-07-25 |
| PE20151934A1 (es) | 2015-12-26 |
| HK1215191A1 (zh) | 2016-08-19 |
| CN105377256A (zh) | 2016-03-02 |
| US20170095453A1 (en) | 2017-04-06 |
| AU2014264421A1 (en) | 2015-12-03 |
| JP2016518398A (ja) | 2016-06-23 |
| WO2014181108A1 (en) | 2014-11-13 |
| CA2911671A1 (en) | 2014-11-13 |
| EP2994131A1 (en) | 2016-03-16 |
| US20170312254A1 (en) | 2017-11-02 |
| ECSP15051434A (es) | 2017-05-31 |
| IN2013MU01696A (Direct) | 2015-06-26 |
| PH12015502557A1 (en) | 2016-02-22 |
| US20160120847A1 (en) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288961A (en) | Pharmaceutical preparations | |
| SMT201900684T1 (it) | Composizione farmaceutica combinata | |
| PL2943181T3 (pl) | Kompozycje farmaceutyczne | |
| GB201322602D0 (en) | Pharmaceutical compounds | |
| GB201306610D0 (en) | Pharmaceutical compounds | |
| ZA201408333B (en) | Pharmaceutical compositions | |
| PL3043778T3 (pl) | Kompozycje farmaceutyczne zawierające refametinib | |
| AP2015008875A0 (en) | Low dose pharmaceutical composition | |
| EP3006525A4 (en) | ASPHALT-URETHANE COMPOSITION | |
| IL244380A0 (en) | Pharmaceutical compounds | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| SG11201509194SA (en) | Radiomitigating pharmaceutical formulations | |
| IL245705A0 (en) | Pharmaceutical dosage forms | |
| HUP1300496A2 (hu) | Stabil kombinációs gyógyszerkészítmény | |
| GB201312386D0 (en) | Pharmaceutical compounds | |
| GB201413253D0 (en) | Solid dosage form | |
| IL244365A0 (en) | pharmaceutical preparation | |
| AP2015008890A0 (en) | Pharmaceutical compositions | |
| GB201304699D0 (en) | Pharmaceutical compositions | |
| GB201317166D0 (en) | Pharmaceutical compounds | |
| GB201304625D0 (en) | New pharmaceutical composition | |
| GB201321497D0 (en) | Pharmaceutical compositions | |
| GB201312851D0 (en) | Pharmaceutical compositions | |
| GB201316780D0 (en) | Pharmaceutical compounds | |
| GB201316791D0 (en) | Pharmaceutical Compounds |